AstraZeneca doubles down on hot cancer target, paying $63M for ADC months after bispecific deal

AstraZeneca is doubling down on the hot cancer target Claudin18.2, paying KYM Biosciences $63 million upfront for the global rights to an early-phase antibody-drug conjugate (ADC). The deal comes 10 months after the Big Pharma entered the space by paying $25 million upfront for a bispecific antibody.